Your session is about to expire
← Back to Search
Glutamate Receptor Antagonist
perampanel for Essential Tremor
Phase 2
Waitlist Available
Led By Charles A Handforth, M.D.
Research Sponsored by VA Greater Los Angeles Healthcare System
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 40 weeks
Awards & highlights
Study Summary
Obtain information on whether the medication Perampanel reduces tremor in people with essential tremor and is well-tolerated.
Eligible Conditions
- Essential Tremor
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 40 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~40 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Safety. Laboratory testing; screen visit testing
Safety. vitals;
Safety; laboratory testing
+5 moreSecondary outcome measures
QOLIE changes
Subjective assessment of global life changes
Treatment effects on Daily Living (The QUEST scale to assess quality of life)
Side effects data
From 2021 Phase 4 trial • 54 Patients • NCT0328812928%
Dizziness
17%
Fatigue
15%
Somnolence
11%
Vomiting
9%
Nasopharyngitis
9%
Irritability
9%
Headache
7%
Nausea
7%
Ear infection
6%
Upper respiratory tract infection
6%
Balance disorder
6%
Memory impairment
6%
Aggression
6%
Depression
6%
Oropharyngeal pain
2%
Mental status changes
2%
Sudden unexplained death in epilepsy
2%
Transient ischaemic attack
2%
Suicidal ideation
100%
80%
60%
40%
20%
0%
Study treatment Arm
Perampanel 12 mg
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: perampanelExperimental Treatment1 Intervention
Perampanel administration
Group II: placeboPlacebo Group1 Intervention
Placebo administered to subjects.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Perampanel
FDA approved
Find a Location
Who is running the clinical trial?
VA Greater Los Angeles Healthcare SystemLead Sponsor
51 Previous Clinical Trials
8,553 Total Patients Enrolled
2 Trials studying Essential Tremor
41 Patients Enrolled for Essential Tremor
Charles A Handforth, M.D.Principal InvestigatorVHAGLAHS
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Share this study with friends
Copy Link
Messenger